Sana CEO outlines growth plans after opening Bothell facility
Headquartered in Seattle, Sana Biotechnology opened its new 80,000 square-foot manufacturing facility in Bothell, Washington, which will house Sana’s proprietary cancer drug program.
Sana utilizes cell engineering to develop treatments for cancer, diabetes, autoimmune diseases and central nervous system disorders. Sana CEO Steve Harr plans to employ more than 60 workers at the facility in the coming months and to eventually have hundreds of employees at the Bothell site in five-plus years.
Harr chose Bothell for the new facility due to its strong workforce and partnerships with local government, further solidifying Bothell’s reputation as an emerging center within the rapidly expanding life science hub of the greater Puget Sound.